4572 Stock Overview
Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Carna Biosciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥468.00 |
52 Week High | JP¥1,060.00 |
52 Week Low | JP¥414.00 |
Beta | 1.24 |
1 Month Change | 4.23% |
3 Month Change | -12.36% |
1 Year Change | 0.43% |
3 Year Change | -65.44% |
5 Year Change | -56.63% |
Change since IPO | -55.00% |
Recent News & Updates
Shareholder Returns
4572 | JP Life Sciences | JP Market | |
---|---|---|---|
7D | -0.6% | 1.0% | 1.0% |
1Y | 0.4% | -29.6% | 38.6% |
Return vs Industry: 4572 exceeded the JP Life Sciences industry which returned -29.6% over the past year.
Return vs Market: 4572 underperformed the JP Market which returned 38.6% over the past year.
Price Volatility
4572 volatility | |
---|---|
4572 Average Weekly Movement | 5.2% |
Life Sciences Industry Average Movement | 6.0% |
Market Average Movement | 3.9% |
10% most volatile stocks in JP Market | 8.3% |
10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 4572 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4572's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 65 | Kohichiro Yoshino | https://www.carnabio.com |
Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan. Its products include kinase proteins, substrates, kinase protein assay kits, and stable cell lines, as well as biotinylated kinases. The company also offers profiling, NanoBRET TE intracellular kinase cell-based assay, protein detection and interaction, live-cell kinase assay, and tyrosine kinase cell-based assay services.
Carna Biosciences, Inc. Fundamentals Summary
4572 fundamental statistics | |
---|---|
Market cap | JP¥7.94b |
Earnings (TTM) | -JP¥1.15b |
Revenue (TTM) | JP¥1.63b |
4.9x
P/S Ratio-7.0x
P/E RatioIs 4572 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4572 income statement (TTM) | |
---|---|
Revenue | JP¥1.63b |
Cost of Revenue | JP¥175.00m |
Gross Profit | JP¥1.45b |
Other Expenses | JP¥2.60b |
Earnings | -JP¥1.15b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -67.19 |
Gross Margin | 89.23% |
Net Profit Margin | -70.89% |
Debt/Equity Ratio | 3.8% |
How did 4572 perform over the long term?
See historical performance and comparison